Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
Also Known As
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Legal Names
Legal name
Similar Companies1000
Cormorant Pharmaceuticals
Cormorant Pharmaceuticals develops therapeutics for cancer and rare diseases.
Sector
Subsector
Keywords
Location
Neuraltus Pharmaceuticals
Neuraltus Pharmaceuticals is a biopharmaceutical company focused on developing therapeutics for neurodegenerative diseases..
Sector
Subsector
Keywords
Location
total rounds
total raised
Aegerion Pharmaceuticals
Aegerion Pharmaceuticals develops and sells therapeutics for cardiovascular and metabolic diseases.
Sector
Subsector
Location
total rounds
total raised
Erimos Pharmaceuticals
Erimos Pharmaceuticals develops small molecule therapeutics to treat cancer and viral diseases.
Sector
Subsector
Keywords
Location
Financials
Funding Rounds3
Number of Funding Rounds
Money Raised
Their latest funding was raised on 28.03.2024. Their latest investor Apollo Health Ventures. Their latest round Series A
Hevolution
Hevolution Foundation supports independent research and entrepreneurship in the field of healthspan science.
Sector
Subsector
Keywords
Location
count Of Investments
venBio Partners
venBio is a life sciences investment firm that partners with industry leaders to develop groundbreaking medicines.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Sofinnova Investments
Sofinnova Investments is a venture capital firm that specializes in funding and supporting Life Science and Technology start-ups.
Sector
Subsector
Location
count Of Investments
count Of Exists
Apollo Health Ventures
Apollo Ventures is a German VC firm investing in age-related disease treatments.
Sector
Subsector
Keywords
Location
total rounds
count Of Investments
Co-Investors
Investors7
Number of lead investors
Number of investors
Apollo Health Ventures
Apollo Ventures is a German VC firm investing in age-related disease treatments.
Sector
Subsector
Keywords
Location
total rounds
count Of Investments
Hevolution
Hevolution Foundation supports independent research and entrepreneurship in the field of healthspan science.
Sector
Subsector
Keywords
Location
count Of Investments
William Greene
William Greene, M.D., joined MPM in 2002 and has led investments in biopharmaceuticals, medical devices and pharma services. Bill is currently serving as CEO of MPM portfolio company Iconic Therapeutics, Inc., which is developing novel therapeutics for ophthalmologic diseases and cancer. He currently also sits on the Board of Sai Advantium Pharma. Bill’s Board and investment experience includes Alnara (acquired by Eli Lilly:LLY), Alsius (Acquired, Zoll), Barrier Therapeutics (BTRX), Cotherix (CTRX), Idun Pharmaceuticals (acquired by Pfizer:PFE), and Intercell AG (ICLL, Vienna Stock Exchange). In addition to investing and serving on corporate boards, Bill has filled roles with portfolio companies including interim VP of Regulatory Affairs, Chief Medical Officer and Scientific and Clinical Development Advisory Boards. Prior to joining MPM, Bill was at Genentech (acquired by Roche:RHHBY) where he served as a Senior Clinical Scientist and Epidemiologist with responsibilities in clinical strategy, trial design and regulatory affairs in several therapeutic areas at all phases of drug development from translational research through post-marketing studies. His experience there included leading the clinical development of Lucentis® from IND through Phase II. Prior to Genentech, Bill was at Yale Medical School where he studied, taught, and performed clinical research in Internal Medicine and Diagnostic Radiology. He was an Assistant Clinical Professor of Medicine at UCSF from 1998-2005, active on the teaching staff of San Francisco General Hospital. Bill received a B.A. degree from Wesleyan University and an M.D. degree from UCSF. He has been a Robert Wood Johnson Clinical Scholar at Yale (clinical epidemiology) and a Howard Hughes Medical Institute Research Scholar at the NIH (neurobiology). In addition to his work with MPM, Bill’s passion for using biotechnology to address significant unmet human needs extends to global health. He is an advisor to the Bill and Melinda Gates Foundation and is Chairman of the Board of the Global Health Investment Fund, a pioneering initiative supported by the Foundation that brings together investors, philanthropists and industry to forge creative solutions to bring the fruits of biotechnology to the underserved around the world.
current job
Mehmood Khan
Mehmood Khan, MD, FACE, is Senior Vice President and Chief Scientific Officer of PepsiCo, Inc.,where he is responsible for guiding the company’s long-term research strategy and agenda for business opportunities. He provides global leadership and support to division research and development groups in the areas of enterprise research planning, R&D portfolio management, next generation technologies, nutritional standards, food safety and regulation, and quality assurance. He is also working with the divisions to accelerate PepsiCo’s global R&D competencies, capabilities, and talent pipeline. One specific area of interest worth highlighting is in the area of global undernourishment. "PepsiCo is concerned that there are almost 1 billion people in the world who are hungry, and 2 billion with micronutrient deficiencies," Dr. Khan explains. "These nutrition problems hamper the intellectual and physical growth of many in developing countries and limit the economic productivity of these countries." Mehmood is leading PepsiCo in developing a corporate approach to addressing the need for high-quality affordable nutrition. His team is currently scoping the size of the problem in India, South Africa, and Nigeria; working with several corporate and NGO partners to identify the best products and delivery systems needed; and working with internal business units to build a sustainable financing model. "The current food and nutrition crises are set to drive over 100 million people into poverty. PepsiCo's approach involves leveraging our core business capabilities (including our R&D, distribution, agriculture, and marketing areas) and drawing upon the best outside groups to work with-these include the Global Alliance for Improved Nutrition, UNICEF, the World Food Program, leading nutrition scientists and USAID. We hope to launch pilot studies in India and South Africa during 2009," Dr. Khan says. Prior to joining PepsiCo in 2007, Mehmood served as President of Takeda Global Research & Development Center, Inc (TGRD). In this role, he led all aspects of TGRD’s business, in both its Deerfield and UK offices, including developing new product candidates, conducting post-marketing clinical studies, and identifying and developing innovative lifecycle management approaches for marketed drugs. He was formerly Senior Vice President of Medical & Scientific Affairs for Takeda Pharmaceuticals North America (TPNA), Inc. With 20 years of experience in both the academic and clinical arenas, Dr. Khan led all aspects of TPNA's Medical and Scientific Affairs departmen
current job
btov Partners
Btov Partners is a Berlin-based venture capital firm investing in early-stage digital and industrial technology companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
People
Founders1
Stelios Tzannis
Stelios Tzannis is the Founder and COO of Aeovian Pharmaceuticals.
current job
organization founded
Stelios Tzannis